Biomarkers of sensitivity and resistance
26 Oct 2016
Biomarkers of sensitivity and resistance
Editor's ESMO 2016 roundup
ESMO 2016 conference highlights
Left versus right sided GI tumour response in the CRYSTAL trial
Highlights of ESMO 2016
Cabozantinib over sunitinib for metastatic renal cell carcinoma
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)
Phase I results of a novel FGFR inhibitor
Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer
Combining drugs with radiotherapy
A novel biomarker for paediatic tumours
ALK mutations in paediatric tumours